Hims & Hers Health, Inc. has added the Multi-Cancer Test by Galleri® to its Labs offering, enabling customers to screen annually for signals associated with more than 50 types of cancer before symptoms appear. The test combines targeted methylation analysis developed by GRAIL with Hims & Hers’ digital platform, addressing cancers without routine screenings—such as pancreatic and ovarian—while complementing existing protocols for breast, cervical, colorectal, prostate and lung. More than one in three people will develop cancer over their lifetime, and early detection can dramatically improve treatment outcomes. The test is offered at a $250 discount to the Galleri list price for existing Labs subscribers.

This launch leverages Hims & Hers’ national reach—over 2.1 million subscribers as of year-end 2025—to scale access to Galleri’s validated multi-cancer early detection (MCED) technology. GRAIL’s CLIA-certified laboratory has demonstrated, in a validation cohort of 6,600 participants, the ability to detect cancer signals with specificity above 99% and to predict the tissue of origin with 88% accuracy. Hims & Hers CEO Andrew Dudum highlighted that integrating this breakthrough into a direct-to-consumer model helps close the access gap in preventive oncology.

Starting today, customers in eligible states can add the Multi-Cancer Test to their Labs subscription through hims.com/labs/cancer-test or forhers.com/labs/cancer-test. The bundled subscription renews on the Labs anniversary date, and eligibility requires an adult customer—preferably age 50 or older, per safety guidelines—who holds an active Labs plan. Hims & Hers projects that 15% of core Labs subscribers will elect the add-on in the first quarter, driving incremental monthly recurring revenue and enhancing lifetime customer value through expanded preventive care offerings.

Hims & Hers will release its fourth quarter and full year 2025 results after market close on February 23, 2026, and host a live conference call at 5:00 p.m. ET (U.S.: 888-510-2630; International: 646-960-0137; Conference ID: 1704296). The webcast will be archived on investors.hims.com for one year. Management is also scheduled to participate in the Morgan Stanley Technology, Media & Telecom Conference on March 2, 2026 in San Francisco, providing investors with further insights into upcoming growth initiatives and profitability timelines.